What is the optimal choice of antihypertensive therapy based on: the class-specific effects or special properties of a drug?


Cite item

Full Text

Abstract

The review article presents data on the significance of activation of different components of the renin-angiotensin-aldosterone system (RAAS) in metabolic disorder progression and organ damage processes. Based on the analysis of the pharmacological properties of drugs and clinical evidence, the authors discuss the problems of the choice of RAAS blockers. The mechanisms of drug action on metabolic processes, atherogenesis, and vascular damage are discussed.

Full Text

На чем основывается оптимальный выбор антигипертензивной терапии: на специфических для класса эффектах или особых свойствах препарата?. - Аннотация. В обзорной статье представлены данные о значении активизации различных компонентов ренин-ангиотензин-альдостероновой системы (РААС) в прогрессировании метаболических расстройств и процессах пвреждения органов. На основании анализа фармакологических свойств препаратов и данных клинических исследований обсуждаются вопросы выбора средств, блокирующих РААС. Рассматриваются механизмы влияния препаратов на метаболические процессы, атерогенез, повреждение сосудов.
×

References

  1. Paul M.., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
  2. Dzau V.J., Bernstein K., Celermajer D. et al. For the Working Group on Tissue Angiotensin-Converting Enzyme, International Society of Cardiovascular Pharmacotherapy. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88: 1-20.
  3. Re R.N. Intracellular renin and the nature of intracrine enzymes. Hypertension 2003; 42: 117-22.
  4. Johnoston C.I., Fabris B., Yamada T. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertension 1989; 7 (5): S11-17.
  5. Vaziri N.D., Rodríguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clin Pract Nephrol 2006; 2 (10): 582-593.
  6. Griengling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity incultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
  7. Sohn H.Y., Raff U., Hoffman A. еt al. Differential role of angiotensin II receptor subtypes on endothelial O2-formation. Br J Pharmacol 2000; 131: 667-672.
  8. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury. Part 1: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916.
  9. Pepine C.J., Celermajer D.S., Drexler H. Vascular health as a therapeutic target in cardiovascular disease. University of Florida 1998; 42.
  10. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindorpil. Expert Rev Cardiovasc Ther 2005; 30: 15-29.
  11. Ceconi C., Fox K.M., Remme W.J. et al. ACE inhibition with perindopril and endothelial dysfunction: results of a substudy of the EUROPA study PERTINENT. Cardiovasc Res 2007; 73: 237-246.
  12. Rodriguez-Granillo G.A. Long-term effect of Perindopril on coronary atherosclerosis progression [from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE) Study]. Am J Cardiol 2007; 100: 159-163.
  13. Cangiano E., Marchesini J., Campo G. et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs 2011; 11: 189-198.
  14. Haier G.R., van Haeften T.W., Vesseren F.L.J. Adipose tissue disfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
  15. Hodge A.M., Boyko E.J., de Courten M. et al. Leptin and other component of the metabolic syndrome in Mauritius: a factor analysis. Int J Obes 2001; 25: 126-131.
  16. Engeli S., Negrel R., Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Yepertension 2000; 35 (6): 1270-1277.
  17. Недогода С.В. Ожирение и артериальная гипертензия: теория и практика выбора оптимального антигипертензивного препарата. М: Медиком 2012; 80.
  18. Недогода С.В., Морозова Т.Е. Возможности коррекции нарушений липидного обмена ингибиторами ангиотензин-превращающего фермента в реальной клинической практике. Consilium medicum 2012; 1: 3-6.
  19. Мычка В.Б., Масенко В.П., Творогова М.Г. и др. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия 2002; 8: 36-41.
  20. Lau T., Carlsson P.O., Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248.
  21. Abuissa H., Jones P.G., Marso S.P., O'Keefe J.H. Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
  22. Fogari R. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316-320.
  23. Brugts J.J., Ninomiya T., Boersma E. et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPE, and PROGRESS trials. Eur Heart J 2009; 30 (11): 1385-1394.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies